AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
South Korea will invest 520 billion won in biotechnology next year to boost its development of treatment and vaccines for COVID-19.
The Ministry of Science and ICT said the figure represents a 24.9 percent hike from 2020.
Of that amount, 31.7 billion won will go to COVID-19 treatment and vaccine development and 10.2 billion won for technology to respond to new infectious diseases.
Some of it will also go to research into new core biotech industries, such as 71 billion won to develop a new medicine, 61.8 billion won in medical devices, and 31.1 billion won in regenerative medicine to strengthen research in stem cell technology and others.
The medical devices to be developed targets the elderly and the disabled.
The ministry said it also plans to invest 51.3 billion won to acquire next-generation biotech, such as single-cell analysis.
Last month, 36 South Korean biotech and pharmaceutical companies announced that they invest a combined 10 trillion won by 2023 to hone their competitiveness and technological capabilities.
The firms include Samsung Biologics Co. and Celltrion Inc., will
The government intends to spend a total of 2.2 trillion won on developing new medicine until 2030.
